BNTX

BioNTech SE

NASDAQ· Healthcare· Biotechnology

$102.08-8.37%

Key metrics

Market cap: $25.64B
P/E: —
Forward P/E: —
P/B: 1.2x
Dividend yield: —
EPS: -$7.18
ROE: -9.30%
Profit margin: -63.64%
Revenue growth: -59.50%
Beta: 1.28
52-week high: $124.00
52-week low: $79.52

History

How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.

Equity, revenue and profitEquityRevenueNet income

The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.

Revenue4 years

Net debtDebt minus cash — below zero means more cash than debt

Dividend per share1 years

Investors holding this

Major managers that reported this stock in their latest 13F.

About the company

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Employees: 7,807
Headquarters: Mainz, Germany
Website: biontech.de

Company description provided by Yahoo Finance.